Redx Pharma

£34.3m raise extends runway through key data points

Lighthouse | 7 June 2022

Share this note

  • Redx Pharma successfully raised £34.3m (gross) on May 19 via the placing of 58.1m new shares at the then market price of 59p per share. The placing was over-subscribed, hence raising more than the planned c £30m. Existing major holders supported the raise, with a new specialist fund also participating. Redmile remains the largest shareholder, with Sofinnova, Polar Capital, and Platinum Healthcare joined on the register by the healthcare specialist Invus. Following the passing of the required resolutions at the General Meeting, the new shares were admitted to trading on June 7.
  • New funds, together with existing resources and likely milestone payments from partners, will support the development of lead in-house assets, RXC004 (Porcupine inhibitor for genetically selected cancers) and RXC007 (ROCK2 inhibitor for major fibrotic diseases) to key clinical data points. Additionally, the recently selected development candidate, RXC008, will be progressed through to IND for fibrostenotic Crohn’s disease. RXC008, a novel GI-targeted ROCK inhibitor, is another example of Redx’s medicinal chemistry expertise that could become a first-in-class therapy.
  • RXC004 is under study in two multi-arm Phase II trials as monotherapy and in combination with a PD-1 checkpoint inhibitor. PORCUPINE is exploring RNF43 and/or RSPO fusion selected patients with aberrant microsatellite stable (MSS) metastatic colorectal cancer (mCRC) with both monotherapy and nivolumab combination arms. PORCUPINE2 is examining monotherapy and an anti-PD1 combination in biliary tract cancer (BTC), where selection is not required as BTC typically has a high Wnt ligand dependency (>70% of cases), and monotherapy in selected pancreatic ductal adenocarcinoma, PDAC. First proof-of-concept trial data could become available during H123.
  • RXC007, a highly selective ROCK2 inhibitor, is due to start a Phase IIa study during H222 for IPF (idiopathic pulmonary fibrosis). ROCK is a central node in fibrosis-associated signalling pathways but addressing it safely has proved difficult. RXC007 appears promising, with preclinical evidence suggesting that Redx’s medicinal chemistry expertise has the potential to overcome these limitations. Initial Phase II data could be available by end-2023.

Trinity Delta view: Successfully raising money against a challenging environment for the sector, coupled with the current macroeconomic backdrop, is a testament to strength of the Redx Pharma investment case. Doing so without a share price discount and raising more than expected suggests the quality of the equity story is beginning to be truly appreciated. The fund raise removes a financial overhang, providing an extra year of cash runway through to key data points. We believe Redx Pharma has a well-balanced clinical pipeline of in-house and partnered assets that should provide a stream of news flow over the next 12-18 months as development progresses. The quality of the discovery engine should also deliver three wholly owned IND assets by 2025. We intend to review our rNPV model following this placing and issue a revised valuation as soon as practicable.


7 June 2022

Market Cap£169.3m
Primary exchangeAIM London
Company CodeREDX
Corporate clientYes

Company description

Redx Pharma specialises in the discovery and development of small molecule therapeutics, with an emphasis on oncology and fibrotic diseases. It aims to initially progress them through proof-of-concept studies, before evaluating options for further development and potential value creation.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2022 Trinity Delta Research Limited. All rights reserved.